ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma
Dr Jeffrey Weber discusses adjuvant and neoadjuvant therapy in melanoma.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 25, 2024 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news
Neoadjuvant Bests Adjuvant Therapy in Lung Cancer Neoadjuvant Bests Adjuvant Therapy in Lung Cancer
Dr Mark Kris discusses neoadjuvant therapy for patients with lung cancer.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 24, 2024 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news
Has Immunotherapy Found Its Place in Pancreatic Cancer? Has Immunotherapy Found Its Place in Pancreatic Cancer?
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant
WEDNESDAY, April 17, 2024 -- Bilateral Wilms tumors (BWTs) that increase in size during neoadjuvant chemotherapy, especially in younger patients, are most often stromal-predominant, according to a study published online March 27 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2024 Category: Pharmaceuticals Source Type: news
ImPrint Identifies Treatment for Patients With Breast Cancer ImPrint Identifies Treatment for Patients With Breast Cancer
Data from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer
(MedPage Today) -- SAN DIEGO -- A preoperative combination of chemotherapy and immunotherapy (IO) appeared safe and effective for borderline resectable pancreatic cancer in a small pilot study, a researcher reported here.
In the phase I/II trial... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 11, 2024 Category: Gastroenterology Source Type: news
UltraCon: Harmonic motion imaging tracks breast tumor response to chemo
AUSTIN -- Harmonic motion imaging can track mechanical property changes of breast tumors in response to neoadjuvant chemotherapy, a study presented April 9 at UltraCon found.
In his presentation, Yangpei Liu from Columbia University in New York City discussed findings from his team’s study, which showed that harmonic motion imaging could be a predictor of early treatment response.
“Harmonic motion imaging-derives changes in tumor mechanical properties are more robust in early complete pathologic response prediction than tumor sizes,” Liu said.Yangpei Liu from Columbia University in Ney York City discussed findings ...
Source: AuntMinnie.com Headlines - April 10, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Womens Imaging Source Type: news
'Excellent' Outcomes After Complete Response in Lymph Node-Positive Breast Cancer
(MedPage Today) -- Patients with early lymph node-positive breast cancer and pathologic complete response (pCR) after neoadjuvant therapy had similar long-term recurrence rates and survival regardless of the type of adjuvant therapy they received... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 27, 2024 Category: Hematology Source Type: news
Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC? Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?
A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
QT Imaging to deliver Breast Acoustic CT scanner to research centers
QT Imaging Holdings is delivering its Breast Acoustic CT scanner in collaboration with research centers in the U.S. and Canada.
The company is collaborating with the Department of Radiation Oncology and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, and the University of Illinois, Urbana-Champaign. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach that can accurately identify early response of breast cancer patients to neoadjuvant ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Is semiannual mammo after breast conserving surgery necessary?
Annual mammography with a clinical exam -- rather than semiannual -- is “likely sufficient” for women who have undergone breast-conserving surgery and were treated with neoadjuvant therapy, a study published March 2 in Surgical Oncology Insight has found. Researchers led by Ton Wang, MD, from Cedars-Sinai Medical Center in Los Angeles found insufficient evidence supporting the use of semiannual mammography in these women, with less than 2% of women developing locoregional recurrence on routine surveillance. “Semiannual mammography is associated with unnecessary benign biopsies, which may increase health care costs ...
Source: AuntMinnie.com Headlines - March 8, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Imaging Source Type: news
Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news
In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
(MedPage Today) -- Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 28, 2024 Category: American Health Source Type: news
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of event-free survival (EFS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news
